Heart Failure
Conditions
Keywords
Bioavailability, pharmacokinetics, enalapril, enalaprilat
Brief summary
Phase I study in healthy adult male and female volunteers to compare the bioavailability of enalapril administered in orodispersible Minitablets with or without water in comparison to the standard galenic tablet formulation of enalapril. The standard pharmacokinetic parameters will be calculated from the bioanalytical results for enalapril and enalaprilat and compared in a descriptive statistical analysis.
Detailed description
Trial design: Open label, randomized, 3-way cross-over, 3-treatments, 3-periods in 24 healthy male and female adult subjects. Primary objectives: 1. To assess the relative bioavailability of 10 mg enalapril administered as orodispersible minitablets (ODMT) with water versus a standard enalapril tablet formulation (reference product: Renitec® 2 x 5 mg tablets) taken with water; 2. To assess the relative bioavailability of 10 mg enalapril administered as orodispersible minitablets (ODMT) dispersed in the oral cavity versus a standard enalapril tablet formulation (reference product: Renitec® 2 x 5 mg tablets) taken with water. Secondary objectives: 1. To assess whether the PK of enalapril is affected when the orodispersible minitablet (ODMT) is entirely swallowed with water versus dispersion in the oral cavity. 2. To assess the general safety and tolerability including local tolerability and palatability of enalapril administered as orodispersible minitablet (ODMT).
Interventions
DRUGEnalapril
oral administration
Sponsors
European Commission
Ethicare GmbH
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male and female subjects aged between 18 and 55 years, inclusive. 2. Body mass index (BMI) between 18.5 and 30 kg/m2 inclusive (BMI = weight/height2). 3. Non-smoker (not smoked for at least 3 months prior to screening). 4. Physical examinations, clinical laboratory values, vital signs and ECGs are clinically acceptable to the investigator. 5. Subjects must have signed an informed consent document indicating that they understand the purpose of, and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions.
Exclusion criteria
1. History or evidence of clinically significant disorder (including psychiatric), condition or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. 2. Women who are lactating/breastfeeding. 3. Women planning to become pregnant during the duration of the study. 4. Men with pregnant partners or whose partners plan to become pregnant during the study. 5. Positive pregnancy test (women) on screening or predose. 6. A baseline systolic BP ≥ 140 or \< 90 mmHg and/or a baseline diastolic BP of ≥ 90 or \<50 mmHg. A baseline ECG QTcB \> 440 ms (males) or \>450 ms (females) or heart rate \>100 bpm. 7. Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen, or hepatitis C antibodies at screening. 8. Known substance abuse (eg, alcohol, illicit or illegal drugs) within 1 year of dosing. 9. Positive test for drug or alcohol use at screening. If the retest during the screening period is negative, subject can be included. 10. Inability or unwillingness to refrain from alcohol consumption 24 hours prior to study visits and to limit consumption throughout the course of the study. 11. Has had major surgery, donated or lost 500 mL or more of blood within 2 months of the first study treatment or has a history of chronic anemia. 12. Receiving or has received any investigational drug (or is currently using an investigational drug or device) within 30 days or 5 half-lives (whichever is longer), prior to receiving the first study treatment. 13. Use of any over-the-counter or prescription medications within 7 days or 5 half-lives (whichever is longer), prior to receiving the first study treatment. However, if a subject has to use medication within 7 days of the first study drug administration, he/she can be included in the study the study if according to the investigator the medication is not relevant within the context of the trial. Paracetamol (up to 2 g per day) for analgesia, and hormonal birth control medication will be allowed. 14. Use of any herbal medicines (eg. St. John's wort), vitamins, and supplements consumed by the subject within 7 days prior to receiving the first study treatment. However, if a subject has used herbal medicines (eg, St. John's wort), vitamins, and supplements medication within 7 days of the first study drug administration, he/she can be included in the study if according to the investigator the medication is not relevant within the context of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC 0-∞ | predose, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hours,1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose | Area under the serum concentration-time curve from time of administration to infinite time for enalaprilat |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability Outcome Parameter | Immediately and 10 minutes after orodispersible minitablet administration | orodispersible minitablet palatability questionnaire |
| AUC 0-∞ | predose, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hours,1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose | Area under the serum-concentration time curve from time of administration extrapolated to infinite time for enalapil |
| AUC 0-t | predose, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hours,1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose | Area under the serum concentration-time curve from from administration to the last measurable concentration or last sampling time point (48h) for enalapril |
| Safety parameters | 0-48 hours post dose, at follow-up visit | adverse events |
| tmax | predose, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hours,1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose | Time of maximum serum concentration of enalapril |
| Ae | 0-2, 2-4, 4-8, 8-12, 12-24, 24-36, 36-48 hours post-dose | Amount of enalaprilat or the sum of enalapril and enalaprilat excreted in urine over the time interval 0-t |
| Cmax | predose, 10 min, 20 min, 30 min, 45 min, 1 hour, 1.25 hours,1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose | Maximum serum concentration for enalapril |
Countries
Belgium
Outcome results
None listed